Ironwood Pharmaceuticals, Inc. (IRWD) financial statements (2023 and earlier)
Company profile
| Business Address |
100 SUMMER STREET, SUITE 2300 BOSTON, MA 02110 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 620 | 363 | 177 | 173 | 221 | 305 | 439 | ||
| Cash and cash equivalents | 620 | 363 | 177 | 173 | 126 | 54 | 261 | ||
| Short-term investments | 96 | 251 | 178 | ||||||
| Restricted cash and investments | 1 | 2 | 1 | 1 | |||||
| Receivables | 114 | 122 | 117 | 81 | 82 | 65 | 55 | ||
| Inventory, net of allowances, customer advances and progress billings | 1 | 1 | 1 | ||||||
| Inventory | 1 | 1 | 1 | ||||||
| Derivative instruments and hedges, assets | 1 | ||||||||
| Other undisclosed current assets | 9 | 9 | 11 | 11 | 7 | 9 | 6 | ||
| Total current assets: | 745 | 496 | 307 | 266 | 312 | 380 | 500 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 15 | 17 | 18 | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 8 | 9 | 12 | 17 | 17 | 21 | 21 | ||
| Long-term investments and receivables | 24 | 23 | 33 | ||||||
| Accounts and financing receivable, after allowance for credit loss | 24 | 23 | 33 | ||||||
| Intangible assets, net (including goodwill) | 1 | 1 | 161 | 167 | |||||
| Goodwill | 1 | 1 | 1 | 1 | |||||
| Intangible assets, net (excluding goodwill) | 160 | 166 | |||||||
| Derivative instruments and hedges | 13 | 31 | 41 | 108 | 133 | 86 | |||
| Restricted cash and investments | 0 | 0 | 1 | 6 | 8 | 9 | |||
| Deferred income tax assets | 333 | ✕ | ✕ | ✕ | ✕ | ||||
| Other noncurrent assets | 1 | 1 | 0 | 0 | 1 | 1 | 3 | ||
| Other undisclosed noncurrent assets | 7 | ||||||||
| Total noncurrent assets: | 382 | 63 | 96 | 66 | 294 | 330 | 119 | ||
| TOTAL ASSETS: | 1,127 | 559 | 403 | 332 | 606 | 710 | 619 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 22 | 18 | 34 | 60 | 54 | 56 | 32 | ||
| Accounts payable | 1 | 1 | 4 | 18 | 16 | 18 | 9 | ||
| Accrued liabilities | 3 | 3 | 11 | 15 | 13 | 38 | 23 | ||
| Employee-related liabilities | 17 | 13 | 19 | 26 | 24 | ||||
| Taxes payable | 0 | ||||||||
| Interest and dividends payable | 0 | 2 | 0 | 1 | 1 | ||||
| Deferred revenue | 1 | ✕ | ✕ | ✕ | ✕ | ||||
| Debt | 117 | 1 | 48 | 4 | 6 | 28 | |||
| Deferred rent credit | 0 | ✕ | ✕ | ✕ | |||||
| Derivative instruments and hedges, liabilities | 1 | ||||||||
| Restructuring reserve | 0 | 11 | 0 | 3 | |||||
| Due to related parties | 2 | 0 | 0 | ||||||
| Business combination, contingent consideration, liability | 0 | 0 | 14 | ||||||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | 0 | 8 | 13 | ||
| Other undisclosed current liabilities | 22 | 3 | 3 | 8 | 7 | 7 | 4 | ||
| Total current liabilities: | 162 | 32 | 41 | 120 | 66 | 91 | 76 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 356 | 451 | 430 | 366 | 132 | 133 | |||
| Long-term debt, excluding current maturities | 337 | 430 | 408 | 366 | 132 | 133 | |||
| Capital lease obligations | ✕ | ✕ | ✕ | 0 | 0 | 0 | |||
| Operating lease, liability | 18 | 20 | 22 | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 4 | 14 | 25 | 43 | 134 | 185 | 94 | ||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | 5 | 1 | 8 | ||
| Deferred rent credit | 6 | ✕ | ✕ | ✕ | |||||
| Other liabilities | 4 | 2 | 1 | 3 | 5 | 8 | 10 | ||
| Business combination, contingent consideration, liability | 31 | 63 | |||||||
| Derivative instruments and hedges, liabilities | 12 | 24 | 34 | 92 | 113 | 75 | |||
| Total noncurrent liabilities: | 359 | 464 | 455 | 409 | 134 | 318 | 227 | ||
| Total liabilities: | 521 | 497 | 496 | 528 | 200 | 409 | 303 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | 606 | 63 | (93) | (196) | 10 | 67 | 95 | ||
| Common stock | 0 | 0 | 0 | ||||||
| Additional paid in capital | 1,543 | 1,529 | 1,479 | 1,395 | 1,319 | 1,258 | 1,205 | ||
| Accumulated other comprehensive loss | (0) | (0) | (0) | ||||||
| Accumulated deficit | (938) | (1,466) | (1,572) | (1,591) | (1,309) | (1,192) | (1,110) | ||
| Other undisclosed stockholders' equity attributable to parent | 0 | 0 | 0 | 0 | |||||
| Total stockholders' equity: | 606 | 63 | (93) | (196) | 10 | 67 | 95 | ||
| Other undisclosed liabilities and equity | 396 | 234 | 221 | ||||||
| TOTAL LIABILITIES AND EQUITY: | 1,127 | 559 | 403 | 332 | 606 | 710 | 619 | ||
Income statement (P&L) ($ in millions)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 414 | 390 | 428 | 347 | 298 | 274 | 150 | |
| Cost of revenue | (3) | (24) | (33) | (19) | (2) | (0) | ||
| Cost of goods and services sold | (3) | (24) | (33) | (0) | (18) | |||
| Gross profit: | 414 | 386 | 405 | 314 | 279 | 272 | 150 | |
| Operating expenses | (182) | (243) | (291) | (584) | (388) | (314) | (234) | |
| Other undisclosed operating income (loss) | 0 | 7 | 31 | 31 | (10) | (18) | ||
| Operating income (loss): | 232 | 143 | 120 | (239) | (77) | (52) | (102) | |
| Nonoperating expense | (32) | (34) | (61) | (43) | (40) | (30) | (41) | |
| Investment income, nonoperating | (0) | (5) | 6 | (6) | (1) | 9 | (9) | |
| Interest and debt expense | (31) | (29) | (31) | (38) | (2) | (39) | (31) | |
| Income (loss) from continuing operations before equity method investments, income taxes: | 170 | 79 | 28 | (320) | (119) | (121) | (174) | |
| Other undisclosed income from continuing operations before income taxes | 31 | 29 | ||||||
| Income (loss) from continuing operations before income taxes: | 201 | 109 | 28 | (320) | (119) | (121) | (174) | |
| Income tax expense (benefit) | 328 | (3) | ||||||
| Other undisclosed income from continuing operations | 31 | |||||||
| Income (loss) from continuing operations: | 528 | 106 | 59 | (320) | (119) | (121) | (174) | |
| Loss from discontinued operations | (37) | |||||||
| Income (loss) before gain (loss) on sale of properties: | 528 | 106 | 22 | (320) | (119) | (121) | (174) | |
| Other undisclosed net income | 38 | 2 | ||||||
| Net income (loss) attributable to parent: | 528 | 106 | 22 | (282) | (117) | (121) | (174) | |
| Other undisclosed net income available to common stockholders, basic | 39 | 31 | ||||||
| Net income (loss) available to common stockholders, diluted: | 528 | 106 | 22 | (282) | (117) | (82) | (143) | |
Comprehensive Income ($ in millions)
| 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | 528 | 106 | 22 | (282) | (117) | (121) | (174) | |
| Comprehensive income (loss): | 528 | 106 | 22 | (282) | (117) | (121) | (174) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 0 | (0) | 39 | 31 | ||||
| Comprehensive income (loss), net of tax, attributable to parent: | 528 | 106 | 22 | (282) | (117) | (82) | (143) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.